Fedratinib is an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.
Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis. Fedratinib has been associated with a high rate of serum enzyme elevations during therapy but has been associated with only rare instances of clinically apparent acute liver injury.
Fedratinib Hydrochloride is the monohydrate dihydrochloride salt form of fedratinib, an orally bioavailable, small-molecule, ATP-competitive inhibitor of Janus-associated kinase 2 (JAK2) and FMS-like tyrosine kinase 3 (FLT3; CD135; STK1; FLK2), with potential antineoplastic activity. Upon oral administration, fedratinib competes with wild-type JAK2 as well as mutated forms for ATP binding, which may result in inhibition of JAK2 activation, inhibition of the JAK-STAT signaling pathway, inhibition of tumor cell proliferation and induction of tumor cell apoptosis. JAK2 is the most commonly mutated gene in bcr-abl-negative myeloproliferative disorders (MPDs). In addition, fedratinib targets bind to, and inhibit the activity of FLT3. This inhibits uncontrolled FLT3 signaling and results in the inhibition of proliferation in tumor cells overexpressing FLT3. FLT3, a class III receptor tyrosine kinase (RTK), is overexpressed or mutated in most B-lineage neoplasms and in acute myeloid leukemias and plays a key role in tumor cell proliferation.
Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high-risk primary and secondary myelofibrosis. It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019.
Mechanism of Action
Fedratinib is an inhibitor of Janus Activated Kinase 2 (JAK2) and FMS-like tyrosine kinase 3. JAK2 is highly active in myeloproliferative neoplasms like myelofibrosis. Fedratinib’s inhibition of JAK2 inhibits phosphorylation of signal transducer and activator of transcription (STAT) 3 and 5, which prevents cell division and induces apoptosis.
Fedratinib is a kinase inhibitor that inhibits cell division and induces apoptosis. Patients taking fedratinib may experience anemia, thrombocytopenia, gastrointestinal toxicity, hepatic toxicity, or elevated amylase and lipase. These effects should be managed by reducing the dose, temporarily stopping the medication, or providing transfusions on a case-by-case basis.
Fedratinib acts as a competitive inhibitor of protein kinase JAK-2 with IC50=6 nM; related kinases FLT3 and RET are also sensitive, with IC50=25 nM and IC50=17 nM, respectively. Significantly less activity was observed against other tyrosine kinases including JAK3 (IC50=169 nM). In treated cells, the inhibitor blocks downstream cellular signaling (JAK-STAT) leading to the suppression of proliferation and induction of apoptosis.
Indications
- Fedratinib is indicated to treat adults with primary or secondary myelofibrosis that is either intermediate-2 or high-risk.
- Arabic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythemia vera myelofibrosis, or post essential thrombocythaemia myelofibrosis who are Janus Associated Kinase (JAK) inhibitor naïve or have been treated with ruxolitinib.
- Fedratinib is an oral selective inhibitor of Janus-associated kinase 2 (JAK-2) and FMS-like tyrosine kinase 3 (FLT3) that is used in the therapy of intermediate or high-risk, primary or secondary myelofibrosis
- Fedratinib hydrochloride is approved for use in adults to treat: Myelofibrosis (a bone marrow disease) that is an intermediate-2 risk or high risk, including the following types: Primary myelofibrosis. Post-polycythemia vera myelofibrosis. Post-essential thrombocythemia myelofibrosis.
- Fedratinib hydrochloride is also being studied in the treatment of other conditions.
- For the treatment of intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF)
- In the United States, fedratinib is indicated for the treatment of adults with intermediate-2 or high-risk primary or secondary (following polycythemia vera or essential thrombocythemia) myelofibrosis.
- Primary Myelofibrosis (PMF)
- Secondary Myelofibrosis
Use in Cancer
Toremifene is approved to treat:
- Breast cancer that has metastasized (spread to other parts of the body). It is used in postmenopausal women whose cancer is estrogen receptor-positive (ER+) or when it is not known if the cancer is ER+ or estrogen receptor-negative (ER-).
Contraindications
- A High Alanine Transaminase Level
- A High Aspartate Transaminase Level
- Low Amount Of Sodium In The Blood
- Decreased Blood Platelets
- A Type Of Brain Function Problem Called Encephalopathy
- High Blood Pressure
- A Low Supply Of Oxygen Rich Blood To The Heart
- Heart Failure
- High Blood Levels Of The Lipase Enzyme
- High Blood Levels Of The Amylase Enzyme
- Difficult Or Painful Urination
- Wernicke’s Encephalopathy
Dosage
Strengths: 100 mg
Myelofibrosis
For patients with a baseline platelet count of 50 x 109/L or greater:
- 400 mg orally once a day
Management of thiamine levels and Wernicke’s encephalopathy (WE):
- Assess thiamine levels and nutritional status prior to starting therapy, periodically during therapy, and as indicated.
- Do not initiate this drug in patients with thiamine deficiency; replete thiamine prior to therapy initiation and during therapy if thiamine levels are low.
- If Wernicke’s encephalopathy is suspected, immediately discontinue therapy and initiate parenteral thiamine treatment.
- Monitor until symptoms resolve or improve and thiamine levels normalize.
Dose Adjustments
- Discontinue therapy in patients unable to tolerate 200 mg daily. Consider dose reductions in patients who become transfusion-dependent during therapy with this drug.
DOSE MODIFICATIONS WITH CONCOMITANT USE OF STRONG CYP450 3A4 INHIBITORS:
- Reduce the dose of this drug when administering with strong CYP450 3A4 inhibitors to 200 mg orally once a day.
- If the strong CYP450 3A4 inhibitor is discontinued, increase the dose of this drug to 300 mg orally once d day during the first 2 weeks after discontinuation of the CYP450 3A4 inhibitor, and then to 400 mg orally once a day thereafter as tolerated.
DOSE MODIFICATIONS FOR HEMATOLOGIC ADVERSE REACTIONS:
- Grade 4 thrombocytopenia or Grade 3 thrombocytopenia with active bleeding: Withhold therapy until resolved to Grade 2 or less or baseline; restart at 100 mg daily below the last given dose.
- Grade 4 Neutropenia: Withhold therapy until resolved to Grade 2 or less or baseline, restart dose at 100 mg daily below the last given dose.
`DOSE MODIFICATIONS FOR NONHEMATOLOGIC ADVERSE REACTIONS:
- Grade 3 or higher nausea, vomiting, or diarrhea not responding to supportive measures within 48 hours: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose.
- Grade 3 or higher ALT, AST, or bilirubin: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose; monitor ALT, AST, and bilirubin (total and direct) more frequently following the dose reduction; if reoccurrence of Grade 3 or higher elevation, discontinue therapy.
- Grade 3 or higher other nonhematologic toxicities: Withhold therapy until resolved to Grade 1 or less or baseline; restart dose at 100 mg daily below the last given dose.
Administration advice:
- This drug may be taken with or without food.
- Administration of a high-fat meal may reduce the incidence of nausea and vomiting.
- If a dose is missed, the next scheduled dose should be taken the following day.
- Patients taking ruxolitinib before initiation of this drug should taper and discontinue according to the ruxolitinib prescribing information.
Side Effects
The Most Common
- nausea
- vomiting
- diarrhea
- constipation
- tiredness
- muscle spasms
- arm, leg, or bone pain
- headache
- weight gain
- dizziness
- unusual bleeding or bruising
- fever, chills, cough, painful or frequent urination, or other signs of infection
- nausea, extreme tiredness, unusual bruising or bleeding, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes, or flu-like symptoms
- shortness of breath, fast heartbeat, headache, dizziness, pale skin, confusion, or tiredness
- pain in the chest, arms, back, neck, jaw, or stomach; breaking out in cold sweat; lightheadedness
- slow or difficult speech; sudden weakness or numbness of the face, arm or leg; sudden headache; sudden vision problems; sudden difficulty walking
- swelling, pain, tenderness, warmth or redness in one or both legs
- shortness of breath, coughing up blood, fast heartbeat, fast breathing, pain when breathing deeply
More common
- Black, tarry stools
- bleeding gums
- blood in the urine or stools
- chills
- cough
- fever
- lower back or side pain
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- sore throat
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- Bone pain
- diarrhea
- dizziness
- headache
- lack or loss of strength
- muscle spasms
- nausea
- pain in the arms or legs
- vomiting
- weight gain
Rare
- Bladder pain
- cloudy urine
- confusion
- difficult, burning, or painful urination
- drowsiness
- frequent urge to urinate
- lower back or side pain
- shakiness and unsteady walk
- trouble remembering
- uncontrolled eye movements
- unsteadiness, trembling, or other problems with muscle control or coordination
Drug Interactions
DRUG | INTERACTION |
---|---|
Abaloparatide | The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Fedratinib. |
Abametapir | The serum concentration of Fedratinib can be increased when it is combined with Abametapir. |
Abatacept | The metabolism of Fedratinib can be increased when combined with Abatacept. |
Abemaciclib | The serum concentration of Abemaciclib can be increased when it is combined with Fedratinib. |
Abrocitinib | The serum concentration of Fedratinib can be increased when it is combined with Abrocitinib. |
Acebutolol | The metabolism of Acebutolol can be decreased when combined with Fedratinib. |
Acenocoumarol | The metabolism of Fedratinib can be decreased when combined with Acenocoumarol. |
Acetaminophen | The serum concentration of Acetaminophen can be increased when it is combined with Fedratinib. |
Acyclovir | The excretion of Acyclovir can be decreased when combined with Fedratinib. |
Adalimumab | The metabolism of Fedratinib can be increased when combined with Adalimumab. |
Afatinib | The serum concentration of Afatinib can be increased when it is combined with Fedratinib. |
Albendazole | The metabolism of Fedratinib can be decreased when combined with Albendazole. |
Allopurinol | Fedratinib may decrease the excretion rate of Allopurinol which could result in a higher serum level. |
Almotriptan | The metabolism of Almotriptan can be decreased when combined with Fedratinib. |
Alogliptin | The metabolism of Alogliptin can be decreased when combined with Fedratinib. |
Alpelisib | The serum concentration of Alpelisib can be increased when it is combined with Fedratinib. |
Ambrisentan | The serum concentration of Ambrisentan can be increased when it is combined with Fedratinib. |
Aminophenazone | The metabolism of Aminophenazone can be decreased when combined with Fedratinib. |
Amiodarone | The metabolism of Fedratinib can be decreased when combined with Amiodarone. |
Amitriptyline | The metabolism of Amitriptyline can be decreased when combined with Fedratinib. |
Amoxapine | The metabolism of Amoxapine can be decreased when combined with Fedratinib. |
Amphetamine | The metabolism of Amphetamine can be decreased when combined with Fedratinib. |
Amprenavir | The metabolism of Fedratinib can be decreased when combined with Amprenavir. |
Anakinra | The metabolism of Fedratinib can be increased when combined with Anakinra. |
Antipyrine | The metabolism of Antipyrine can be decreased when combined with Fedratinib. |
Apalutamide | The serum concentration of Fedratinib can be increased when it is combined with Apalutamide. |
Apixaban | Fedratinib may decrease the excretion rate of Apixaban which could result in a higher serum level. |
Apremilast | The metabolism of Fedratinib can be increased when combined with Apremilast. |
Aprepitant | The metabolism of Fedratinib can be decreased when combined with Aprepitant. |
Arformoterol | The metabolism of Arformoterol can be decreased when combined with Fedratinib. |
Aripiprazole | The metabolism of Aripiprazole can be decreased when combined with Fedratinib. |
Aripiprazole lauroxil | The metabolism of Aripiprazole lauroxil can be decreased when combined with Fedratinib. |
Armodafinil | The metabolism of Fedratinib can be decreased when combined with Armodafinil. |
Arsenic trioxide | The serum concentration of Fedratinib can be increased when it is combined with Arsenic trioxide. |
Artemether | The metabolism of Fedratinib can be decreased when combined with Artemether. |
Artenimol | The metabolism of Fedratinib can be decreased when combined with Artenimol. |
Articaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Articaine. |
Asciminib | The serum concentration of Fedratinib can be increased when it is combined with Asciminib. |
Astemizole | The metabolism of Astemizole can be decreased when combined with Fedratinib. |
Asunaprevir | The serum concentration of Fedratinib can be increased when it is combined with Asunaprevir. |
Atazanavir | The metabolism of Fedratinib can be decreased when combined with Atazanavir. |
Atenolol | The metabolism of Atenolol can be decreased when combined with Fedratinib. |
Atogepant | The serum concentration of Atogepant can be increased when it is combined with Fedratinib. |
Atomoxetine | The metabolism of Atomoxetine can be decreased when combined with Fedratinib. |
Atorvastatin | The excretion of Atorvastatin can be decreased when combined with Fedratinib. |
Avanafil | The serum concentration of Avanafil can be increased when it is combined with Fedratinib. |
Avatrombopag | The serum concentration of Avatrombopag can be increased when it is combined with Fedratinib. |
Axitinib | The serum concentration of Axitinib can be increased when it is combined with Fedratinib. |
Azelastine | The metabolism of Azelastine can be decreased when combined with Fedratinib. |
Baricitinib | The excretion of Baricitinib can be decreased when combined with Fedratinib. |
Belantamab | The serum concentration of Belantamab mafodotin can be increased when it is combined with Fedratinib. |
Belinostat | The serum concentration of Belinostat can be increased when it is combined with Fedratinib. |
Belumosudil | The serum concentration of Fedratinib can be increased when it is combined with Belumosudil. |
Belzutifan | The metabolism of Belzutifan can be decreased when combined with Fedratinib. |
Bempedoic acid | The excretion of Bempedoic acid can be decreased when combined with Fedratinib. |
Bendamustine | The serum concentration of Bendamustine can be increased when it is combined with Fedratinib. |
Benzatropine | The metabolism of Benzatropine can be decreased when combined with Fedratinib. |
Benzocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzocaine. |
Benzyl alcohol | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Benzyl alcohol. |
Benzylpenicillin | The excretion of Benzylpenicillin can be decreased when combined with Fedratinib. |
Bepridil | The metabolism of Bepridil can be decreased when combined with Fedratinib. |
Berotralstat | The serum concentration of Berotralstat can be increased when it is combined with Fedratinib. |
Betaxolol | The metabolism of Betaxolol can be decreased when combined with Fedratinib. |
Betrixaban | The serum concentration of Betrixaban can be increased when it is combined with Fedratinib. |
Bimekizumab | The metabolism of Fedratinib can be increased when combined with Bimekizumab. |
Binimetinib | The serum concentration of Binimetinib can be increased when it is combined with Fedratinib. |
Bisoprolol | The serum concentration of Bisoprolol can be increased when it is combined with Fedratinib. |
Boceprevir | The metabolism of Fedratinib can be decreased when combined with Boceprevir. |
Bortezomib | The serum concentration of Bortezomib can be increased when it is combined with Fedratinib. |
Bosentan | The excretion of Bosentan can be decreased when combined with Fedratinib. |
Bosutinib | The serum concentration of Bosutinib can be increased when it is combined with Fedratinib. |
Brentuximab | The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib. |
Brexpiprazole | The metabolism of Brexpiprazole can be decreased when combined with Fedratinib. |
Brigatinib | Fedratinib may decrease the excretion rate of Brigatinib which could result in a higher serum level. |
Brincidofovir | The serum concentration of Brincidofovir can be increased when it is combined with Fedratinib. |
Bupivacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Bupivacaine. |
Buprenorphine | The metabolism of Fedratinib can be decreased when combined with Buprenorphine. |
Buspirone | The metabolism of Buspirone can be decreased when combined with Fedratinib. |
Butacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butacaine. |
Butamben | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Butamben. |
Cabazitaxel | The serum concentration of Cabazitaxel can be increased when it is combined with Fedratinib. |
Cabergoline | The serum concentration of Cabergoline can be increased when it is combined with Fedratinib. |
Canagliflozin | The serum concentration of Fedratinib can be increased when it is combined with Canagliflozin. |
Canakinumab | The metabolism of Fedratinib can be increased when combined with Canakinumab. |
Cannabidiol | The metabolism of Fedratinib can be decreased when combined with Cannabidiol. |
Capmatinib | The serum concentration of Fedratinib can be increased when it is combined with Capmatinib. |
Capsaicin | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Capsaicin. |
Carbamazepine | The metabolism of Fedratinib can be increased when combined with Carbamazepine. |
Carbimazole | The therapeutic efficacy of Carbimazole can be decreased when used in combination with Fedratinib. |
Carfilzomib | The serum concentration of Carfilzomib can be increased when it is combined with Fedratinib. |
Carisoprodol | The metabolism of Fedratinib can be decreased when combined with Carisoprodol. |
Carvedilol | The serum concentration of Fedratinib can be increased when it is combined with Carvedilol. |
Caspofungin | The excretion of Caspofungin can be decreased when combined with Fedratinib. |
Cefradine | The excretion of Cefradine can be decreased when combined with Fedratinib. |
Celecoxib | Fedratinib may decrease the excretion rate of Celecoxib which could result in a higher serum level. |
Celiprolol | The metabolism of Celiprolol can be decreased when combined with Fedratinib. |
Cenobamate | The serum concentration of Fedratinib can be decreased when it is combined with Cenobamate. |
Cephalexin | The excretion of Cephalexin can be decreased when combined with Fedratinib. |
Ceritinib | The serum concentration of Ceritinib can be increased when it is combined with Fedratinib. |
Cerivastatin | Fedratinib may decrease the excretion rate of Cerivastatin which could result in a higher serum level. |
Certolizumab | The metabolism of Fedratinib can be increased when combined with Certolizumab pegol. |
Cevimeline | The metabolism of Cevimeline can be decreased when combined with Fedratinib. |
Chloramphenicol | The metabolism of Fedratinib can be decreased when combined with Chloramphenicol. |
Chloroprocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Chloroprocaine. |
Chloroquine | The metabolism of Chloroquine can be decreased when combined with Fedratinib. |
Chlorpheniramine | The metabolism of Chlorpheniramine can be decreased when combined with Fedratinib. |
Chlorpromazine | The metabolism of Chlorpromazine can be decreased when combined with Fedratinib. |
Chlorzoxazone | The metabolism of Chlorzoxazone can be decreased when combined with Fedratinib. |
Cholecystokinin | The excretion of Cholecystokinin can be decreased when combined with Fedratinib. |
Cholic Acid | The excretion of Cholic Acid can be decreased when combined with Fedratinib. |
Ciclesonide | The metabolism of Ciclesonide can be decreased when combined with Fedratinib. |
Cilostazol | The metabolism of Cilostazol can be decreased when combined with Fedratinib. |
Cimetidine | The metabolism of Fedratinib can be decreased when combined with Cimetidine. |
Cinchocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cinchocaine. |
Cinnarizine | The metabolism of Cinnarizine can be decreased when combined with Fedratinib. |
Ciprofloxacin | The metabolism of Fedratinib can be decreased when combined with Ciprofloxacin. |
Citalopram | The metabolism of Fedratinib can be decreased when combined with Citalopram. |
Cladribine | Fedratinib may decrease the excretion rate of Cladribine which could result in a higher serum level. |
Clarithromycin | The metabolism of Fedratinib can be decreased when combined with Clarithromycin. |
Clevidipine | The metabolism of Fedratinib can be decreased when combined with Clevidipine. |
Clobazam | The serum concentration of Clobazam can be increased when it is combined with Fedratinib. |
Clofarabine | Fedratinib may decrease the excretion rate of Clofarabine which could result in a higher serum level. |
Clofazimine | The serum concentration of Fedratinib can be increased when it is combined with Clofazimine. |
Clomifene | The serum concentration of Clomifene can be increased when it is combined with Fedratinib. |
Clomipramine | The metabolism of Clomipramine can be decreased when combined with Fedratinib. |
Clonidine | The metabolism of Clonidine can be decreased when combined with Fedratinib. |
Clopidogrel | The metabolism of Fedratinib can be decreased when combined with Clopidogrel. |
Clozapine | The metabolism of Fedratinib can be decreased when combined with Clozapine. |
Cobicistat | The metabolism of Fedratinib can be decreased when combined with Cobicistat. |
Cobimetinib | The serum concentration of Cobimetinib can be increased when it is combined with Fedratinib. |
Cocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Cocaine. |
Codeine | The metabolism of Codeine can be decreased when combined with Fedratinib. |
Colchicine | The serum concentration of Colchicine can be increased when it is combined with Fedratinib. |
Conivaptan | The metabolism of Fedratinib can be decreased when combined with Conivaptan. |
Conjugated | Fedratinib may decrease the excretion rate of Conjugated estrogens which could result in a higher serum level. |
Copanlisib | The serum concentration of Copanlisib can be increased when it is combined with Fedratinib. |
Crizotinib | The serum concentration of Crizotinib can be increased when it is combined with Fedratinib. |
Curcumin | The metabolism of Fedratinib can be decreased when combined with Curcumin. |
Cyclophosphamide | The metabolism of Fedratinib can be decreased when combined with Cyclophosphamide. |
Cyclosporine | The serum concentration of Cyclosporine can be increased when it is combined with Fedratinib. |
Dabigatran etexilate | The serum concentration of Dabigatran etexilate can be increased when it is combined with Fedratinib. |
Dabrafenib | The serum concentration of Fedratinib can be decreased when it is combined with Dabrafenib. |
Daclatasvir | The serum concentration of Fedratinib can be increased when it is combined with Daclatasvir. |
Dacomitinib | The serum concentration of Dacomitinib can be increased when it is combined with Fedratinib. |
Dactinomycin | The serum concentration of Dactinomycin can be increased when it is combined with Fedratinib. |
Danazol | The metabolism of Fedratinib can be decreased when combined with Danazol. |
Dapagliflozin | The metabolism of Dapagliflozin can be decreased when combined with Fedratinib. |
Daptomycin | The serum concentration of Daptomycin can be increased when it is combined with Fedratinib. |
Darbepoetin alfa | The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Fedratinib. |
Darifenacin | The metabolism of Darifenacin can be decreased when combined with Fedratinib. |
Darolutamide | Fedratinib may decrease the excretion rate of Darolutamide which could result in a higher serum level. |
Darunavir | The metabolism of Fedratinib can be decreased when combined with Darunavir. |
Dasabuvir | The serum concentration of Dasabuvir can be increased when it is combined with Fedratinib. |
Dasatinib | The serum concentration of Dasatinib can be increased when it is combined with Fedratinib. |
Daunorubicin | Fedratinib may decrease the excretion rate of Daunorubicin which could result in a higher serum level. |
Debrisoquine | The metabolism of Debrisoquine can be decreased when combined with Fedratinib. |
Delafloxacin | Fedratinib may decrease the excretion rate of Delafloxacin which could result in a higher serum level. |
Delavirdine | The metabolism of Fedratinib can be decreased when combined with Delavirdine. |
Desipramine | The metabolism of Desipramine can be decreased when combined with Fedratinib. |
Desvenlafaxine | The metabolism of Fedratinib can be decreased when combined with Desvenlafaxine. |
Deutetrabenazine | The metabolism of Deutetrabenazine can be decreased when combined with Fedratinib. |
Dexamethasone | The metabolism of Fedratinib can be increased when combined with Dexamethasone. |
Dexchlorpheniramine | The metabolism of Dexchlorpheniramine maleate can be decreased when combined with Fedratinib. |
Dexfenfluramine | The metabolism of Dexfenfluramine can be decreased when combined with Fedratinib. |
Dexlansoprazole | The metabolism of Fedratinib can be decreased when combined with Dexlansoprazole. |
Dextroamphetamine | The metabolism of Dextroamphetamine can be decreased when combined with Fedratinib. |
Dextromethorphan | The metabolism of Dextromethorphan can be decreased when combined with Fedratinib. |
Dextropropoxyphene | The metabolism of Dextropropoxyphene can be decreased when combined with Fedratinib. |
Diazepam | The metabolism of Fedratinib can be decreased when combined with Diazepam. |
Digitoxin | The serum concentration of Digitoxin can be increased when it is combined with Fedratinib. |
Digoxin | Fedratinib may decrease the excretion rate of Digoxin which could result in a higher serum level. |
Dihydrocodeine | The metabolism of Dihydrocodeine can be decreased when combined with Fedratinib. |
Diltiazem | The metabolism of Fedratinib can be decreased when combined with Diltiazem. |
Dimethyl sulfoxide | The metabolism of Fedratinib can be decreased when combined with Dimethyl sulfoxide. |
Dinoprostone | The excretion of Dinoprostone can be decreased when combined with Fedratinib. |
Diosmin | The serum concentration of Fedratinib can be increased when it is combined with Diosmin. |
Diphenhydramine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Diphenhydramine. |
Docetaxel | The excretion of Docetaxel can be decreased when combined with Fedratinib. |
Dolasetron | The metabolism of Dolasetron can be decreased when combined with Fedratinib. |
Dolutegravir | Fedratinib may decrease the excretion rate of Dolutegravir which could result in a higher serum level. |
Domperidone | The metabolism of Domperidone can be decreased when combined with Fedratinib. |
Donepezil | Fedratinib may decrease the excretion rate of Donepezil which could result in a higher serum level. |
Dosulepin | The metabolism of Dosulepin can be decreased when combined with Fedratinib. |
Doxazosin | The metabolism of Fedratinib can be decreased when combined with Doxazosin. |
Doxepin | The metabolism of Fedratinib can be decreased when combined with Doxepin. |
Doxorubicin | The serum concentration of Doxorubicin can be increased when it is combined with Fedratinib. |
Dronabinol | The metabolism of Fedratinib can be decreased when combined with Dronabinol. |
Dronedarone | The metabolism of Fedratinib can be decreased when combined with Dronedarone. |
Duloxetine | The metabolism of Duloxetine can be decreased when combined with Fedratinib. |
Duvelisib | Fedratinib may decrease the excretion rate of Duvelisib which could result in a higher serum level. |
Dyclonine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Dyclonine. |
Edoxaban | The serum concentration of Edoxaban can be increased when it is combined with Fedratinib. |
Efavirenz | The metabolism of Fedratinib can be decreased when combined with Efavirenz. |
Elagolix | The serum concentration of Fedratinib can be increased when it is combined with Elagolix. |
Elbasvir | The serum concentration of Elbasvir can be increased when it is combined with Fedratinib. |
Eletriptan | The metabolism of Eletriptan can be decreased when combined with Fedratinib. |
Eliglustat | The serum concentration of Fedratinib can be increased when it is combined with Eliglustat. |
Eluxadoline | The serum concentration of Eluxadoline can be increased when it is combined with Fedratinib. |
Elvitegravir | The metabolism of Fedratinib can be decreased when combined with Elvitegravir. |
Emapalumab | The metabolism of Fedratinib can be increased when combined with Emapalumab. |
Emtricitabine | The excretion of Emtricitabine can be decreased when combined with Fedratinib. |
Enalapril | The excretion of Enalapril can be decreased when combined with Fedratinib. |
Enasidenib | The metabolism of Enasidenib can be decreased when combined with Fedratinib. |
Encainide | The metabolism of Encainide can be decreased when combined with Fedratinib. |
Encorafenib | The metabolism of Encorafenib can be decreased when combined with Fedratinib. |
Enfortumab | The serum concentration of Enfortumab vedotin can be increased when it is combined with Fedratinib. |
Entrectinib | The serum concentration of Fedratinib can be increased when it is combined with Entrectinib. |
Enzalutamide | The serum concentration of Fedratinib can be decreased when it is combined with Enzalutamide. |
Epinastine | The metabolism of Epinastine can be decreased when combined with Fedratinib. |
Erdafitinib | The serum concentration of Fedratinib can be increased when it is combined with Erdafitinib. |
Ergotamine | The metabolism of Fedratinib can be decreased when combined with Ergotamine. |
Erlotinib | The metabolism of Erlotinib can be decreased when combined with Fedratinib. |
Ertugliflozin | Fedratinib may decrease the excretion rate of Ertugliflozin which could result in a higher serum level. |
Erythromycin | The metabolism of Fedratinib can be decreased when combined with Erythromycin. |
Erythropoietin | The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Fedratinib. |
Escitalopram | The metabolism of Fedratinib can be decreased when combined with Escitalopram. |
Esketamine | The metabolism of Fedratinib can be decreased when combined with Esketamine. |
Eslicarbazepine | The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine. |
Eslicarbazepine | The metabolism of Fedratinib can be decreased when combined with Eslicarbazepine acetate. |
Esmolol | The metabolism of Esmolol can be decreased when combined with Fedratinib. |
Esomeprazole | The metabolism of Fedratinib can be decreased when combined with Esomeprazole. |
Estradiol | The metabolism of Fedratinib can be decreased when combined with Estradiol. |
Estrone sulfate | The excretion of Estrone sulfate can be decreased when combined with Fedratinib. |
Etanercept | The metabolism of Fedratinib can be increased when combined with Etanercept. |
Ethambutol | The metabolism of Fedratinib can be decreased when combined with Ethambutol. |
Ethanol | The metabolism of Fedratinib can be decreased when combined with Ethanol. |
Ethinylestradiol | The metabolism of Fedratinib can be decreased when combined with Ethinylestradiol. |
Ethyl chloride | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ethyl chloride. |
Etidocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Etidocaine. |
Etoposide | The serum concentration of Etoposide can be increased when it is combined with Fedratinib. |
Etoricoxib | The metabolism of Fedratinib can be decreased when combined with Etoricoxib. |
Etravirine | The metabolism of Fedratinib can be decreased when combined with Etravirine. |
Everolimus | The serum concentration of Everolimus can be increased when it is combined with Fedratinib. |
Ezetimibe | Fedratinib may decrease the excretion rate of Ezetimibe which could result in a higher serum level. |
Favipiravir | The serum concentration of Fedratinib can be increased when it is combined with Favipiravir. |
Felbamate | The metabolism of Fedratinib can be decreased when combined with Felbamate. |
Fenfluramine | The metabolism of Fenfluramine can be decreased when combined with Fedratinib. |
Fenofibrate | The metabolism of Fedratinib can be decreased when combined with Fenofibrate. |
Fesoterodine | The metabolism of Fesoterodine can be decreased when combined with Fedratinib. |
Fexinidazole | The metabolism of Fedratinib can be decreased when combined with Fexinidazole. |
Fexofenadine | The serum concentration of Fexofenadine can be increased when it is combined with Fedratinib. |
Flecainide | The metabolism of Flecainide can be decreased when combined with Fedratinib. |
Flibanserin | The serum concentration of Fedratinib can be increased when it is combined with Flibanserin. |
Fluconazole | The metabolism of Fedratinib can be decreased when combined with Fluconazole. |
Flunarizine | The metabolism of Flunarizine can be decreased when combined with Fedratinib. |
Fluorouracil | Fedratinib may decrease the excretion rate of Fluorouracil which could result in a higher serum level. |
Fluoxetine | The metabolism of Fedratinib can be decreased when combined with Fluoxetine. |
Fluvastatin | The metabolism of Fluvastatin can be decreased when combined with Fedratinib. |
Fluvoxamine | The metabolism of Fedratinib can be decreased when combined with Fluvoxamine. |
Folic acid | Fedratinib may decrease the excretion rate of Folic acid which could result in a higher serum level. |
Follitropin | The therapeutic efficacy of Follitropin can be decreased when used in combination with Fedratinib. |
Formoterol | The metabolism of Fedratinib can be decreased when combined with Formoterol. |
Fosnetupitant | The metabolism of Fedratinib can be decreased when combined with Fosnetupitant. |
Fosphenytoin | The metabolism of Fedratinib can be increased when combined with Fosphenytoin. |
Fostemsavir | Fedratinib may decrease the excretion rate of Fostemsavir which could result in a higher serum level. |
Fusidic acid | The metabolism of Fedratinib can be decreased when combined with Fusidic acid. |
Futibatinib | The serum concentration of Futibatinib can be increased when it is combined with Fedratinib. |
Gadoxetic acid | The excretion of Gadoxetic acid can be decreased when combined with Fedratinib. |
Galantamine | The metabolism of Galantamine can be decreased when combined with Fedratinib. |
Ganciclovir | The excretion of Ganciclovir can be decreased when combined with Fedratinib. |
Gefitinib | Fedratinib may decrease the excretion rate of Gefitinib which could result in a higher serum level. |
Gemcitabine | The serum concentration of Gemcitabine can be increased when it is combined with Fedratinib. |
Gemfibrozil | The metabolism of Fedratinib can be decreased when combined with Gemfibrozil. |
Gilteritinib | The serum concentration of Gilteritinib can be increased when it is combined with Fedratinib. |
Glasdegib | Fedratinib may decrease the excretion rate of Glasdegib which could result in a higher serum level. |
Glecaprevir | Fedratinib may decrease the excretion rate of Glecaprevir which could result in a higher serum level. |
Gliclazide | The metabolism of Fedratinib can be decreased when combined with Gliclazide. |
Glyburide | Fedratinib may decrease the excretion rate of Glyburide which could result in a higher serum level. |
Golimumab | The metabolism of Fedratinib can be increased when combined with Golimumab. |
Grazoprevir | The serum concentration of Grazoprevir can be increased when it is combined with Fedratinib. |
Guanidine | The excretion of Guanidine can be decreased when combined with Fedratinib. |
Haloperidol | The serum concentration of Haloperidol can be increased when it is combined with Fedratinib. |
Hydrocodone | The metabolism of Hydrocodone can be decreased when combined with Fedratinib. |
Hydroxychloroquine | The metabolism of Hydroxychloroquine can be decreased when combined with Fedratinib. |
Ibrutinib | The metabolism of Ibrutinib can be decreased when combined with Fedratinib. |
Idarubicin | The metabolism of Idarubicin can be decreased when combined with Fedratinib. |
Idelalisib | Fedratinib may decrease the excretion rate of Idelalisib which could result in a higher serum level. |
Iloperidone | The metabolism of Iloperidone can be decreased when combined with Fedratinib. |
Imatinib | Fedratinib may decrease the excretion rate of Imatinib which could result in a higher serum level. |
Imipramine | The serum concentration of Imipramine can be increased when it is combined with Fedratinib. |
Indacaterol | The serum concentration of Indacaterol can be increased when it is combined with Fedratinib. |
Indinavir | The metabolism of Fedratinib can be decreased when combined with Indinavir. |
Infliximab | The metabolism of Fedratinib can be increased when combined with Infliximab. |
Inotuzumab | The serum concentration of Inotuzumab ozogamicin can be increased when it is combined with Fedratinib. |
Ipecac | The metabolism of Ipecac can be decreased when combined with Fedratinib. |
Irinotecan | Fedratinib may decrease the excretion rate of Irinotecan which could result in a higher serum level. |
Isavuconazole | The serum concentration of Fedratinib can be increased when it is combined with Isavuconazole. |
Isavuconazonium | The serum concentration of Fedratinib can be increased when it is combined with Isavuconazonium. |
Isoniazid | The metabolism of Fedratinib can be decreased when combined with Isoniazid. |
Isradipine | The metabolism of Fedratinib can be decreased when combined with Isradipine. |
Istradefylline | The serum concentration of Fedratinib can be increased when it is combined with Istradefylline. |
Itraconazole | The metabolism of Fedratinib can be decreased when combined with Itraconazole. |
Ivacaftor | The serum concentration of Fedratinib can be increased when it is combined with Ivacaftor. |
Ivermectin | Fedratinib may decrease the excretion rate of Ivermectin which could result in a higher serum level. |
Ivosidenib | The metabolism of Fedratinib can be increased when combined with Ivosidenib. |
Ixabepilone | The serum concentration of Fedratinib can be increased when it is combined with Ixabepilone. |
Ketoconazole | The metabolism of Fedratinib can be decreased when combined with Ketoconazole. |
Labetalol | The metabolism of Fedratinib can be decreased when combined with Labetalol. |
Lacosamide | The metabolism of Fedratinib can be decreased when combined with Lacosamide. |
Lamivudine | Fedratinib may decrease the excretion rate of Lamivudine which could result in a higher serum level. |
Lansoprazole | The metabolism of Fedratinib can be decreased when combined with Lansoprazole. |
Lapatinib | The serum concentration of Fedratinib can be increased when it is combined with Lapatinib. |
Larotrectinib | The serum concentration of Larotrectinib can be increased when it is combined with Fedratinib. |
Lasmiditan | The serum concentration of Fedratinib can be increased when it is combined with Lasmiditan. |
Ledipasvir | The serum concentration of Ledipasvir can be increased when it is combined with Fedratinib. |
Lefamulin | Fedratinib may decrease the excretion rate of Lefamulin which could result in a higher serum level. |
Leflunomide | Fedratinib may decrease the excretion rate of Leflunomide which could result in a higher serum level. |
Lemborexant | The serum concentration of Lemborexant can be increased when it is combined with Fedratinib. |
Lenvatinib | Fedratinib may decrease the excretion rate of Lenvatinib which could result in a higher serum level. |
Letermovir | The metabolism of Fedratinib can be increased when combined with Letermovir. |
Letrozole | The metabolism of Fedratinib can be decreased when combined with Letrozole. |
Levobetaxolol | The metabolism of Levobetaxolol can be decreased when combined with Fedratinib. |
Levobupivacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Levobupivacaine. |
Levofloxacin | The excretion of Levofloxacin can be decreased when combined with Fedratinib. |
Levoketoconazole | The metabolism of Fedratinib can be decreased when combined with Levoketoconazole. |
Levomilnacipran | The metabolism of Levomilnacipran can be decreased when combined with Fedratinib. |
Levosalbutamol | The excretion of Levosalbutamol can be decreased when combined with Fedratinib. |
Levothyroxine | The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Fedratinib. |
Lidocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Lidocaine. |
Linagliptin | The metabolism of Fedratinib can be decreased when combined with Linagliptin. |
Liothyronine | The therapeutic efficacy of Liothyronine can be decreased when used in combination with Fedratinib. |
Liotrix | The therapeutic efficacy of Liotrix can be decreased when used in combination with Fedratinib. |
Lisdexamfetamine | The metabolism of Lisdexamfetamine can be decreased when combined with Fedratinib. |
Lisuride | The metabolism of Lisuride can be decreased when combined with Fedratinib. |
Lofexidine | The metabolism of Lofexidine can be decreased when combined with Fedratinib. |
Lomitapide | The serum concentration of Fedratinib can be increased when it is combined with Lomitapide. |
Lonafarnib | The metabolism of Fedratinib can be decreased when combined with Lonafarnib. |
Loncastuximab | The serum concentration of Loncastuximab tesirine can be increased when it is combined with Fedratinib. |
Loperamide | The excretion of Loperamide can be decreased when combined with Fedratinib. |
Lopinavir | The metabolism of Fedratinib can be decreased when combined with Lopinavir. |
Lorcaserin | The metabolism of Lorcaserin can be decreased when combined with Fedratinib. |
Lorpiprazole | The metabolism of Lorpiprazole can be decreased when combined with Fedratinib. |
Losartan | The metabolism of Fedratinib can be decreased when combined with Losartan. |
Lovastatin | The metabolism of Fedratinib can be decreased when combined with Lovastatin. |
Loxapine | The serum concentration of Fedratinib can be increased when it is combined with Loxapine. |
Luliconazole | The serum concentration of Fedratinib can be increased when it is combined with Luliconazole. |
Lumacaftor | The serum concentration of Fedratinib can be decreased when it is combined with Lumacaftor. |
Lusutrombopag | Fedratinib may decrease the excretion rate of Lusutrombopag which could result in a higher serum level. |
Lynestrenol | The metabolism of Fedratinib can be decreased when combined with Lynestrenol. |
Manidipine | The metabolism of Fedratinib can be decreased when combined with Manidipine. |
Mannitol | The serum concentration of Mannitol can be increased when it is combined with Fedratinib. |
Maprotiline | The metabolism of Maprotiline can be decreased when combined with Fedratinib. |
Maribavir | The serum concentration of Fedratinib can be increased when it is combined with Maribavir. |
Mavacamten | The serum concentration of Fedratinib can be decreased when it is combined with Mavacamten. |
Meclizine | The metabolism of Meclizine can be decreased when combined with Fedratinib. |
Mefloquine | The serum concentration of Fedratinib can be increased when it is combined with Mefloquine. |
Meloxicam | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Meloxicam. |
Memantine | The metabolism of Fedratinib can be decreased when combined with Memantine. |
Mephenytoin | The metabolism of Fedratinib can be decreased when combined with Mephenytoin. |
Mepivacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Mepivacaine. |
Mesoridazine | The metabolism of Mesoridazine can be decreased when combined with Fedratinib. |
Metamfetamine | The metabolism of Metamfetamine can be decreased when combined with Fedratinib. |
Metformin | The excretion of Metformin can be decreased when combined with Fedratinib. |
Methadone | The metabolism of Fedratinib can be decreased when combined with Methadone. |
Methimazole | The metabolism of Fedratinib can be decreased when combined with Methimazole. |
Methotrexate | Fedratinib may decrease the excretion rate of Methotrexate which could result in a higher serum level. |
Methotrimeprazine | The metabolism of Methotrimeprazine can be decreased when combined with Fedratinib. |
Methoxy | The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Fedratinib. |
Methoxyflurane | The metabolism of Methoxyflurane can be decreased when combined with Fedratinib. |
Methsuximide | The metabolism of Fedratinib can be decreased when combined with Methsuximide. |
Methylene blue | The serum concentration of Fedratinib can be increased when it is combined with Methylene blue. |
Methylphenobar | The metabolism of Fedratinib can be decreased when combined with Methylphenobarbital. |
Metoclopramide | The metabolism of Metoclopramide can be decreased when combined with Fedratinib. |
Metoprolol | The metabolism of Metoprolol can be decreased when combined with Fedratinib. |
Metreleptin | The metabolism of Fedratinib can be increased when combined with Metreleptin. |
Mexiletine | The metabolism of Mexiletine can be decreased when combined with Fedratinib. |
Mianserin | The metabolism of Mianserin can be decreased when combined with Fedratinib. |
Miconazole | The metabolism of Fedratinib can be decreased when combined with Miconazole. |
Midostaurin | The metabolism of Fedratinib can be decreased when combined with Midostaurin. |
Mifepristone | The serum concentration of Fedratinib can be increased when it is combined with Mifepristone. |
Milnacipran | The metabolism of Fedratinib can be decreased when combined with Milnacipran. |
Minaprine | The metabolism of Minaprine can be decreased when combined with Fedratinib. |
Mirabegron | The serum concentration of Fedratinib can be increased when it is combined with Mirabegron. |
Mirtazapine | The metabolism of Mirtazapine can be decreased when combined with Fedratinib. |
Mitapivat | The serum concentration of Fedratinib can be increased when it is combined with Mitapivat. |
Mitotane | The metabolism of Fedratinib can be increased when combined with Mitotane. |
Mitoxantrone | Fedratinib may decrease the excretion rate of Mitoxantrone which could result in a higher serum level. |
Moclobemide | The metabolism of Fedratinib can be decreased when combined with Moclobemide. |
Modafinil | The metabolism of Fedratinib can be decreased when combined with Modafinil. |
Morphine | The serum concentration of Morphine can be increased when it is combined with Fedratinib. |
Mycophenolate | Fedratinib may decrease the excretion rate of Mycophenolate mofetil which could result in a higher serum level. |
Nadolol | The metabolism of Nadolol can be decreased when combined with Fedratinib. |
Naloxegol | The serum concentration of Naloxegol can be increased when it is combined with Fedratinib. |
Naloxone | The metabolism of Fedratinib can be decreased when combined with Naloxone. |
Nateglinide | The metabolism of Nateglinide can be decreased when combined with Fedratinib. |
Nebivolol | The metabolism of Fedratinib can be decreased when combined with Nebivolol. |
Nefazodone | The metabolism of Fedratinib can be decreased when combined with Nefazodone. |
Nelfinavir | The metabolism of Fedratinib can be decreased when combined with Nelfinavir. |
Neratinib | The serum concentration of Fedratinib can be increased when it is combined with Neratinib. |
Netupitant | The metabolism of Fedratinib can be decreased when combined with Netupitant. |
Nevirapine | The metabolism of Nevirapine can be decreased when combined with Fedratinib. |
Nicardipine | The metabolism of Fedratinib can be decreased when combined with Nicardipine. |
Nicergoline | The metabolism of Nicergoline can be decreased when combined with Fedratinib. |
Nifedipine | The metabolism of Nifedipine can be decreased when combined with Fedratinib. |
Nilotinib | The metabolism of Fedratinib can be decreased when combined with Nilotinib. |
Nilutamide | The metabolism of Fedratinib can be decreased when combined with Nilutamide. |
Nilvadipine | The metabolism of Fedratinib can be decreased when combined with Nilvadipine. |
Nintedanib | The serum concentration of Nintedanib can be increased when it is combined with Fedratinib. |
Nitrofurantoin | Fedratinib may decrease the excretion rate of Nitrofurantoin which could result in a higher serum level. |
Norgestimate | The serum concentration of Fedratinib can be increased when it is combined with Norgestimate. |
Nortriptyline | The serum concentration of Nortriptyline can be increased when it is combined with Fedratinib. |
Olanzapine | The metabolism of Fedratinib can be decreased when combined with Olanzapine. |
Oliceridine | The metabolism of Oliceridine can be decreased when combined with Fedratinib. |
Omadacycline | The serum concentration of Omadacycline can be increased when it is combined with Fedratinib. |
Ombitasvir | Fedratinib may decrease the excretion rate of Ombitasvir which could result in a higher serum level. |
Omeprazole | The metabolism of Fedratinib can be decreased when combined with Omeprazole. |
Ondansetron | The metabolism of Ondansetron can be decreased when combined with Fedratinib. |
Opium | The metabolism of Opium can be decreased when combined with Fedratinib. |
Oritavancin | The metabolism of Fedratinib can be decreased when combined with Oritavancin. |
Osilodrostat | The metabolism of Fedratinib can be decreased when combined with Osilodrostat. |
Osimertinib | The serum concentration of Osimertinib can be increased when it is combined with Fedratinib. |
Ouabain | The excretion of Ouabain can be decreased when combined with Fedratinib. |
Oxaliplatin | Fedratinib may decrease the excretion rate of Oxaliplatin which could result in a higher serum level. |
Oxcarbazepine | The metabolism of Fedratinib can be decreased when combined with Oxcarbazepine. |
Oxetacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxetacaine. |
Oxprenolol | The metabolism of Oxprenolol can be decreased when combined with Fedratinib. |
Oxybuprocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Oxybuprocaine. |
Oxycodone | The metabolism of Oxycodone can be decreased when combined with Fedratinib. |
Oxymorphone | The metabolism of Oxymorphone can be decreased when combined with Fedratinib. |
Ozanimod | Fedratinib may decrease the excretion rate of Ozanimod which could result in a higher serum level. |
Paclitaxel | The excretion of Paclitaxel can be decreased when combined with Fedratinib. |
Pacritinib | The serum concentration of Fedratinib can be increased when it is combined with Pacritinib. |
Palbociclib | Fedratinib may decrease the excretion rate of Palbociclib which could result in a higher serum level. |
Paliperidone | The serum concentration of Fedratinib can be increased when it is combined with Paliperidone. |
Palonosetron | The metabolism of Palonosetron can be decreased when combined with Fedratinib. |
Panobinostat | The serum concentration of Panobinostat can be increased when it is combined with Fedratinib. |
Pantoprazole | The metabolism of Fedratinib can be decreased when combined with Pantoprazole. |
Parathyroid | The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Fedratinib. |
Paritaprevir | The serum concentration of Paritaprevir can be increased when it is combined with Fedratinib. |
Paroxetine | The metabolism of Fedratinib can be decreased when combined with Paroxetine. |
Pazopanib | The serum concentration of Pazopanib can be increased when it is combined with Fedratinib. |
Peginesatide | The risk or severity of Thrombosis can be increased when Peginesatide is combined with Fedratinib. |
Penbutolol | The metabolism of Penbutolol can be decreased when combined with Fedratinib. |
Penicillamine | The excretion of Penicillamine can be decreased when combined with Fedratinib. |
Pentamidine | The metabolism of Fedratinib can be decreased when combined with Pentamidine. |
Pentobarbital | The metabolism of Fedratinib can be increased when combined with Pentobarbital. |
Perhexiline | The metabolism of Perhexiline can be decreased when combined with Fedratinib. |
Perphenazine | The metabolism of Perphenazine can be decreased when combined with Fedratinib. |
Phenformin | The metabolism of Phenformin can be decreased when combined with Fedratinib. |
Phenobarbital | The metabolism of Fedratinib can be increased when combined with Phenobarbital. |
Phenol | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Phenol. |
Phenytoin | The metabolism of Fedratinib can be increased when combined with Phenytoin. |
Pibrentasvir | Fedratinib may decrease the excretion rate of Pibrentasvir which could result in a higher serum level. |
Pimozide | The metabolism of Pimozide can be decreased when combined with Fedratinib. |
Pindolol | The metabolism of Pindolol can be decreased when combined with Fedratinib. |
Piperazine | The metabolism of Piperazine can be decreased when combined with Fedratinib. |
Pipotiazine | The metabolism of Pipotiazine can be decreased when combined with Fedratinib. |
Pirfenidone | The metabolism of Fedratinib can be decreased when combined with Pirfenidone. |
Pitavastatin | Fedratinib may decrease the excretion rate of Pitavastatin which could result in a higher serum level. |
Pitolisant | The serum concentration of Fedratinib can be decreased when it is combined with Pitolisant. |
Pomalidomide | The serum concentration of Pomalidomide can be increased when it is combined with Fedratinib. |
Ponatinib | The metabolism of Ponatinib can be decreased when combined with Fedratinib. |
Posaconazole | The metabolism of Fedratinib can be decreased when combined with Posaconazole. |
Potassium Iodide | The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Fedratinib. |
Potassium | The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Fedratinib. |
Practolol | The metabolism of Practolol can be decreased when combined with Fedratinib. |
Pralatrexate | Fedratinib may decrease the excretion rate of Pralatrexate which could result in a higher serum level. |
Pralsetinib | The serum concentration of Pralsetinib can be increased when it is combined with Fedratinib. |
Pramocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Pramocaine. |
Pravastatin | Fedratinib may decrease the excretion rate of Pravastatin which could result in a higher serum level. |
Praziquantel | The metabolism of Fedratinib can be decreased when combined with Praziquantel. |
Prazosin | Fedratinib may decrease the excretion rate of Prazosin which could result in a higher serum level. |
Prednisolone | The serum concentration of Prednisolone phosphate can be increased when it is combined with Fedratinib. |
Prilocaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Prilocaine. |
Primaquine | The metabolism of Fedratinib can be decreased when combined with Primaquine. |
Primidone | The metabolism of Fedratinib can be increased when combined with Primidone. |
Procainamide | The metabolism of Procainamide can be decreased when combined with Fedratinib. |
Procaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Procaine. |
Prochlorperazine | The metabolism of Prochlorperazine can be decreased when combined with Fedratinib. |
Progesterone | The metabolism of Fedratinib can be decreased when combined with Progesterone. |
Proguanil | The metabolism of Fedratinib can be decreased when combined with Proguanil. |
Promazine | The metabolism of Promazine can be decreased when combined with Fedratinib. |
Promethazine | The metabolism of Promethazine can be decreased when combined with Fedratinib. |
Propafenone | The serum concentration of Fedratinib can be increased when it is combined with Propafenone. |
Proparacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Proparacaine. |
Propoxycaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Propoxycaine. |
Propranolol | The metabolism of Fedratinib can be decreased when combined with Propranolol. |
Propylthiouracil | The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Fedratinib. |
Protirelin | The therapeutic efficacy of Protirelin can be decreased when used in combination with Fedratinib. |
Prucalopride | The serum concentration of Prucalopride can be increased when it is combined with Fedratinib. |
Quetiapine | The metabolism of Quetiapine can be decreased when combined with Fedratinib. |
Quinidine | The serum concentration of Quinidine can be increased when it is combined with Fedratinib. |
Quinine | The serum concentration of Fedratinib can be increased when it is combined with Quinine. |
Rabeprazole | The metabolism of Fedratinib can be decreased when combined with Rabeprazole. |
Raloxifene | Fedratinib may decrease the excretion rate of Raloxifene which could result in a higher serum level. |
Ramelteon | The metabolism of Fedratinib can be decreased when combined with Ramelteon. |
Ranolazine | The serum concentration of Ranolazine can be increased when it is combined with Fedratinib. |
Regorafenib | The serum concentration of Regorafenib can be increased when it is combined with Fedratinib. |
Relebactam | The excretion of Relebactam can be decreased when combined with Fedratinib. |
Relugolix | The serum concentration of Relugolix can be increased when it is combined with Fedratinib. |
Remoxipride | The metabolism of Remoxipride can be decreased when combined with Fedratinib. |
Repaglinide | The excretion of Repaglinide can be decreased when combined with Fedratinib. |
Reserpine | The serum concentration of Fedratinib can be increased when it is combined with Reserpine. |
Revefenacin | Fedratinib may decrease the excretion rate of Revefenacin which could result in a higher serum level. |
Ribociclib | The metabolism of Fedratinib can be decreased when combined with Ribociclib. |
Rifabutin | The metabolism of Fedratinib can be increased when combined with Rifabutin. |
Rifampicin | The metabolism of Fedratinib can be increased when combined with Rifampicin. |
Rifamycin | The metabolism of Fedratinib can be increased when combined with Rifamycin. |
Rifapentine | The metabolism of Fedratinib can be increased when combined with Rifapentine. |
Rifaximin | The serum concentration of Rifaximin can be increased when it is combined with Fedratinib. |
Rilonacept | The metabolism of Fedratinib can be increased when combined with Rilonacept. |
Rilpivirine | The metabolism of Fedratinib can be decreased when combined with Rilpivirine. |
Riluzole | Fedratinib may decrease the excretion rate of Riluzole which could result in a higher serum level. |
Rimegepant | The serum concentration of Rimegepant can be increased when it is combined with Fedratinib. |
Riociguat | Fedratinib may decrease the excretion rate of Riociguat which could result in a higher serum level. |
Ripretinib | Fedratinib may decrease the excretion rate of Ripretinib which could result in a higher serum level. |
Risperidone | The metabolism of Risperidone can be decreased when combined with Fedratinib. |
Ritonavir | The serum concentration of Fedratinib can be increased when it is combined with Ritonavir. |
Rivaroxaban | Fedratinib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level. |
Rolapitant | The serum concentration of Fedratinib can be increased when it is combined with Rolapitant. |
Romidepsin | The serum concentration of Romidepsin can be increased when it is combined with Fedratinib. |
Ropivacaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Ropivacaine. |
Rosuvastatin | Fedratinib may decrease the excretion rate of Rosuvastatin which could result in a higher serum level. |
Rotigotine | The metabolism of Rotigotine can be decreased when combined with Fedratinib. |
Rucaparib | Fedratinib may decrease the excretion rate of Rucaparib which could result in a higher serum level. |
Rupatadine | The metabolism of Rupatadine can be decreased when combined with Fedratinib. |
Salmon | The therapeutic efficacy of Salmon calcitonin can be decreased when used in combination with Fedratinib. |
Sapropterin | The serum concentration of Fedratinib can be increased when it is combined with Sapropterin. |
Saquinavir | The metabolism of Fedratinib can be decreased when combined with Saquinavir. |
Sarecycline | The serum concentration of Fedratinib can be increased when it is combined with Sarecycline. |
Satralizumab | The serum concentration of Fedratinib can be decreased when it is combined with Satralizumab. |
Secukinumab | The metabolism of Fedratinib can be increased when combined with Secukinumab. |
Selegiline | The metabolism of Selegiline can be decreased when combined with Fedratinib. |
Selexipag | The serum concentration of Selexipag can be increased when it is combined with Fedratinib. |
Selumetinib | Fedratinib may decrease the excretion rate of Selumetinib which could result in a higher serum level. |
Sertindole | The metabolism of Sertindole can be decreased when combined with Fedratinib. |
Sertraline | The metabolism of Fedratinib can be decreased when combined with Sertraline. |
Sildenafil | The serum concentration of Fedratinib can be increased when it is combined with Sildenafil. |
Silodosin | The excretion of Silodosin can be decreased when combined with Fedratinib. |
Siltuximab | The metabolism of Fedratinib can be increased when combined with Siltuximab. |
Simeprevir | The metabolism of Fedratinib can be decreased when combined with Simeprevir. |
Simvastatin | The serum concentration of Fedratinib can be increased when it is combined with Simvastatin. |
Sincalide | The excretion of Sincalide can be decreased when combined with Fedratinib. |
Sirolimus | The serum concentration of Sirolimus can be increased when it is combined with Fedratinib. |
Sitagliptin | The serum concentration of Sitagliptin can be increased when it is combined with Fedratinib. |
Sitaxentan | The metabolism of Fedratinib can be decreased when combined with Sitaxentan. |
Sofosbuvir | Fedratinib may decrease the excretion rate of Sofosbuvir which could result in a higher serum level. |
Solifenacin | The metabolism of Solifenacin can be decreased when combined with Fedratinib. |
Solriamfetol | The excretion of Solriamfetol can be decreased when combined with Fedratinib. |
Somapacitan | The metabolism of Fedratinib can be decreased when combined with Somapacitan. |
Somatrogon | The metabolism of Fedratinib can be increased when combined with Somatrogon. |
Sorafenib | Fedratinib may decrease the excretion rate of Sorafenib which could result in a higher serum level. |
Sotagliflozin | The serum concentration of Fedratinib can be increased when it is combined with Sotagliflozin. |
Sotalol | The metabolism of Sotalol can be decreased when combined with Fedratinib. |
Sotorasib | The serum concentration of Fedratinib can be decreased when it is combined with Sotorasib. |
St. John’s Wort | The metabolism of Fedratinib can be increased when combined with St. John’s Wort. |
Stiripentol | The metabolism of Fedratinib can be decreased when combined with Stiripentol. |
Sulfasalazine | Fedratinib may decrease the excretion rate of Sulfasalazine which could result in a higher serum level. |
Sumatriptan | Fedratinib may decrease the excretion rate of Sumatriptan which could result in a higher serum level. |
Suvorexant | The serum concentration of Fedratinib can be increased when it is combined with Suvorexant. |
Tacrolimus | The serum concentration of Fedratinib can be increased when it is combined with Tacrolimus. |
Tafenoquine | The metabolism of Tafenoquine can be decreased when combined with Fedratinib. |
Talazoparib | The serum concentration of Talazoparib can be increased when it is combined with Fedratinib. |
Tamoxifen | The metabolism of Tamoxifen can be decreased when combined with Fedratinib. |
Tamsulosin | The metabolism of Tamsulosin can be decreased when combined with Fedratinib. |
Taurocholic acid | The excretion of Taurocholic acid can be decreased when combined with Fedratinib. |
Tazemetostat | Fedratinib may decrease the excretion rate of Tazemetostat which could result in a higher serum level. |
Technetium | The excretion of Technetium Tc-99m mebrofenin can be decreased when combined with Fedratinib. |
Technetium | The serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Fedratinib. |
Tecovirimat | The metabolism of Fedratinib can be decreased when combined with Tecovirimat. |
Tegaserod | Fedratinib may decrease the excretion rate of Tegaserod which could result in a higher serum level. |
Telaprevir | The metabolism of Fedratinib can be decreased when combined with Telaprevir. |
Telithromycin | The metabolism of Fedratinib can be decreased when combined with Telithromycin. |
Telmisartan | The metabolism of Fedratinib can be decreased when combined with Telmisartan. |
Telotristat ethyl | The serum concentration of Fedratinib can be decreased when it is combined with Telotristat ethyl. |
Temsirolimus | The serum concentration of Temsirolimus can be increased when it is combined with Fedratinib. |
Teniposide | Fedratinib may decrease the excretion rate of Teniposide which could result in a higher serum level. |
Tenofovir | The serum concentration of Tenofovir alafenamide can be increased when it is combined with Fedratinib. |
Tenofovir | The serum concentration of Tenofovir disoproxil can be increased when it is combined with Fedratinib. |
Tepotinib | The serum concentration of Tepotinib can be increased when it is combined with Fedratinib. |
Terfenadine | The metabolism of Fedratinib can be decreased when combined with Terfenadine. |
Teriflunomide | Fedratinib may decrease the excretion rate of Teriflunomide which could result in a higher serum level. |
Teriparatide | The therapeutic efficacy of Teriparatide can be decreased when used in combination with Fedratinib. |
Testosterone | Fedratinib may decrease the excretion rate of Testosterone which could result in a higher serum level. |
Testosterone | Fedratinib may decrease the excretion rate of Testosterone cypionate which could result in a higher serum level. |
Testosterone | Fedratinib may decrease the excretion rate of Testosterone enanthate which could result in a higher serum level. |
Tetrabenazine | The metabolism of Tetrabenazine can be decreased when combined with Fedratinib. |
Tetracaine | The risk or severity of methemoglobinemia can be increased when Fedratinib is combined with Tetracaine. |
Tezacaftor | The serum concentration of Tezacaftor can be increased when it is combined with Fedratinib. |
Theophylline | The metabolism of Theophylline can be decreased when combined with Fedratinib. |
Thiopental | The metabolism of Fedratinib can be decreased when combined with Thiopental. |
Thioridazine | The metabolism of Fedratinib can be decreased when combined with Thioridazine. |
Thyroid, porcine | The therapeutic efficacy of Thyroid, porcine can be decreased when used in combination with Fedratinib. |
Thyrotropin alfa | The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Fedratinib. |
Ticagrelor | The serum concentration of Fedratinib can be increased when it is combined with Ticagrelor. |
Ticlopidine | The metabolism of Fedratinib can be decreased when combined with Ticlopidine. |
Timolol | The metabolism of Timolol can be decreased when combined with Fedratinib. |
Tiotropium | The metabolism of Tiotropium can be decreased when combined with Fedratinib. |
Tipranavir | The metabolism of Fedratinib can be decreased when combined with Tipranavir. |
Tivozanib | The serum concentration of Tivozanib can be increased when it is combined with Fedratinib. |
Tocilizumab | The metabolism of Fedratinib can be increased when combined with Tocilizumab. |
Tolterodine | The metabolism of Tolterodine can be decreased when combined with Fedratinib. |
Tolvaptan | The serum concentration of Tolvaptan can be increased when it is combined with Fedratinib. |
Topiramate | The metabolism of Fedratinib can be decreased when combined with Topiramate. |
Topotecan | The serum concentration of Topotecan can be increased when it is combined with Fedratinib. |
Torasemide | The excretion of Torasemide can be decreased when combined with Fedratinib. |
Toremifene | The serum concentration of Fedratinib can be increased when it is combined with Toremifene. |
Trabectedin | The metabolism of Trabectedin can be decreased when combined with Fedratinib. |
Tramadol | The metabolism of Tramadol can be decreased when combined with Fedratinib. |
Tranylcypromine | The metabolism of Fedratinib can be decreased when combined with Tranylcypromine. |
Trastuzumab | The serum concentration of Trastuzumab emtansine can be increased when it is combined with Fedratinib. |
Trazodone | The metabolism of Trazodone can be decreased when combined with Fedratinib. |
Triclabendazole | The metabolism of Fedratinib can be decreased when combined with Triclabendazole. |
Trilaciclib | Fedratinib may decrease the excretion rate of Trilaciclib which could result in a higher serum level. |
Trimethadione | The metabolism of Fedratinib can be decreased when combined with Trimethadione. |
Trimipramine | The serum concentration of Trimipramine can be increased when it is combined with Fedratinib. |
Troleandomycin | The metabolism of Fedratinib can be decreased when combined with Troleandomycin. |
Tucatinib | Tucatinib may decrease the excretion rate of Fedratinib which could result in a higher serum level. |
Ubrogepant | The serum concentration of Ubrogepant can be increased when it is combined with Fedratinib. |
Umbralisib | The serum concentration of Fedratinib can be increased when it is combined with Umbralisib. |
Umeclidinium | The serum concentration of Umeclidinium can be increased when it is combined with Fedratinib. |
Valbenazine | The metabolism of Valbenazine can be decreased when combined with Fedratinib. |
Valproic acid | The metabolism of Fedratinib can be decreased when combined with Valproic acid. |
Valsartan | The excretion of Valsartan can be decreased when combined with Fedratinib. |
Vandetanib | The serum concentration of Fedratinib can be increased when it is combined with Vandetanib. |
Vardenafil | The serum concentration of Fedratinib can be increased when it is combined with Vardenafil. |
Velpatasvir | Fedratinib may decrease the excretion rate of Velpatasvir which could result in a higher serum level. |
Vemurafenib | The serum concentration of Fedratinib can be increased when it is combined with Vemurafenib. |
Venetoclax | The serum concentration of Venetoclax can be increased when it is combined with Fedratinib. |
Venlafaxine | The metabolism of Venlafaxine can be decreased when combined with Fedratinib. |
Verapamil | The metabolism of Fedratinib can be decreased when combined with Verapamil. |
Vernakalant | The metabolism of Vernakalant can be decreased when combined with Fedratinib. |
Vilazodone | The metabolism of Fedratinib can be decreased when combined with Vilazodone. |
Viloxazine | The metabolism of Fedratinib can be decreased when combined with Viloxazine. |
Vinblastine | The serum concentration of Vinblastine can be increased when it is combined with Fedratinib. |
Vincristine | The excretion of Vincristine can be decreased when combined with Fedratinib. |
Vinflunine | The serum concentration of Vinflunine can be increased when it is combined with Fedratinib. |
Voclosporin | The serum concentration of Fedratinib can be increased when it is combined with Voclosporin. |
Vonoprazan | The metabolism of Fedratinib can be decreased when combined with Vonoprazan. |
Vorapaxar | The serum concentration of Fedratinib can be increased when it is combined with Vorapaxar. |
Voriconazole | The serum concentration of Fedratinib can be increased when it is combined with Voriconazole. |
Vortioxetine | The metabolism of Fedratinib can be decreased when combined with Vortioxetine. |
Voxelotor | The metabolism of Voxelotor can be decreased when combined with Fedratinib. |
Voxilaprevir | Fedratinib may decrease the excretion rate of Voxilaprevir which could result in a higher serum level. |
Yohimbine | The metabolism of Yohimbine can be decreased when combined with Fedratinib. |
Zafirlukast | The metabolism of Fedratinib can be decreased when combined with Zafirlukast. |
Zidovudine | Fedratinib may decrease the excretion rate of Zidovudine which could result in a higher serum level. |
Zimelidine | The metabolism of Fedratinib can be decreased when combined with Zimelidine. |
Ziprasidone | The metabolism of Fedratinib can be decreased when combined with Ziprasidone. |
Zolpidem | The metabolism of Fedratinib can be decreased when combined with Zolpidem. |
Zonisamide | The serum concentration of Fedratinib can be increased when it is combined with Zonisamide. |
Zuclopenthixol | The metabolism of Zuclopenthixol can be decreased when combined with Fedratinib. |
Pregnancy and Lactation
US FDA pregnancy category: Not assigned.
Pregnancy
This drug should be used during pregnancy only if the benefit outweighs the risk. Adequate methods of contraception should be encouraged. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential harm to the fetus.
Lactation
- A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
- Excreted into human milk: Unknown
- Excreted into animal milk: Data not available
- Because of the potential for serious adverse reactions in a breastfed child, advise patients not to breastfeed during therapy and for at least 1 month after.
How should this medicine be used?
Fedratinib comes as a capsule to take by mouth. It is usually taken once a day, with or without food. Taking fedratinib with a high fat meal may help to reduce nausea and vomiting. Take fedratinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take fedratinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
Your doctor will order blood tests before and during your treatment to see how you are affected by this medication. Your doctor may increase or decrease your dose of fedratinib during your treatment, or may tell you to stop taking fedratinib temporarily or permanently. This depends on how well the medication works for you, your lab test results, and if you experience side effects. Talk to your doctor about how you are feeling during your treatment.
Other uses for this medicine
This medication may be prescribed for other uses; ask your doctor or pharmacist for more information.
What special precautions should I follow?
Before taking fedratinib,
- tell your doctor and pharmacist if you are allergic to fedratinib, any other medications, or any of the ingredients in fedratinib capsules. Ask your pharmacist or check the Medication Guide for a list of the ingredients.
- tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), diltiazem (Cardizem, Dilacor, Tiazac, others), erythromycin (E.E.S., E-mycin, Erythrocin), idelalisib (Zydelig), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole (Nizoral), metoprolol (Lopressor, Toprol XL, in Dutoprol, others), midazolam (Versed), nefazodone, nelfinavir (Viracept), omeprazole (Prilosec, in Zegerid), pantoprazole (Protonix), ribociclib (Kisqali, Kisqali, in Femera), ritonavir (Norvir), ruxolitinib (Jakafi), and saquinavir (Invirase). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with fedratinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list.
- tell your doctor if you if you smoke or if you have ever smoked. Also tell your doctor if you have or have ever had cancer, pancreatitis (swelling of the pancreas), blood clots, a stroke, a heart attack or other heart problems, liver or kidney disease.
- tell your doctor if you are pregnant or plan to become pregnant. If you become pregnant while taking fedratinib, call your doctor.
- do not breastfeed during your treatment with fedratinib and for at least 1 month after your final dose.
- if you are having surgery, including dental surgery, tell the doctor or dentist that you are taking fedratinib.
References